High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal Ann Surg Oncol (2018) 25:1980–1985 https://doi.org/10.1245/s10434-018-6484-8 OR IGINAL ARTIC L E – COLORECTAL CANCER High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal Blake D. Babcock, MD, Mayada A. Aljehani, DrPH, Brice Jabo, MD, MPH, Audrey H. Choi, MD, John W. Morgan, DrPH, MPH, Matthew J. Selleck, DO, Fabrizio Luca, MD, Elizabeth Raskin, MD, Mark E. Reeves, MD, PhD, Carlos A. Garberoglio, MD, Sharon S. Lum, MD, and Maheswari Senthil, MD Loma Linda University Cancer Center, Loma Linda, CA ABSTRACT 95% CI 0.11–0.61), and T4/LVI (HR 0.16, 95% CI Introduction. Adjuvant chemotherapy is recommended in 0.04–0.61). patients with stage II colon cancer with high-risk features Conclusions. Not all high-risk features have similar (HRF). However, there is no quantification of the amount adverse effects on OS. T4 tumors and their combination of risk conferred by each HRF or the overall survival (OS) with other HRF achieve the most survival benefit with benefit gained by chemotherapy based on the risk factor. adjuvant therapy. Type and number of high-risk features Objective. To assess survival benefits associated with should be taken into consideration when recommending adjuvant chemotherapy among stage II colon cancer adjuvant chemotherapy in stage II colon cancer. patients having http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Loading next page...
 
/lp/springer_journal/high-risk-stage-ii-colon-cancer-not-all-risks-are-created-equal-dlqRzoohFB
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
D.O.I.
10.1245/s10434-018-6484-8
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2018) 25:1980–1985 https://doi.org/10.1245/s10434-018-6484-8 OR IGINAL ARTIC L E – COLORECTAL CANCER High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal Blake D. Babcock, MD, Mayada A. Aljehani, DrPH, Brice Jabo, MD, MPH, Audrey H. Choi, MD, John W. Morgan, DrPH, MPH, Matthew J. Selleck, DO, Fabrizio Luca, MD, Elizabeth Raskin, MD, Mark E. Reeves, MD, PhD, Carlos A. Garberoglio, MD, Sharon S. Lum, MD, and Maheswari Senthil, MD Loma Linda University Cancer Center, Loma Linda, CA ABSTRACT 95% CI 0.11–0.61), and T4/LVI (HR 0.16, 95% CI Introduction. Adjuvant chemotherapy is recommended in 0.04–0.61). patients with stage II colon cancer with high-risk features Conclusions. Not all high-risk features have similar (HRF). However, there is no quantification of the amount adverse effects on OS. T4 tumors and their combination of risk conferred by each HRF or the overall survival (OS) with other HRF achieve the most survival benefit with benefit gained by chemotherapy based on the risk factor. adjuvant therapy. Type and number of high-risk features Objective. To assess survival benefits associated with should be taken into consideration when recommending adjuvant chemotherapy among stage II colon cancer adjuvant chemotherapy in stage II colon cancer. patients having

Journal

Annals of Surgical OncologySpringer Journals

Published: Apr 19, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off